Shinya Sakurai

4PUBLICATIONS
0CO-AUTHORS
PharmacogenomicsPsychiatry (incl. psychotherapy)Toxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 27, 2022
Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results.

Yukari Okubo, Yoshinori Umezawa, Shinya Sakurai

|Nov 26, 2021
Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy.

Shinichi Imafuku, Yayoi Tada, Yoshinori Umezawa

|Apr 22, 2021
Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results.

Yoshinori Umezawa, Akihiko Asahina, Shinichi Imafuku

|Feb 19, 2021
Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study.

Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii

Pageof 1

Frequent Collaborators